李艳

邮箱：yan.li@ynu.edu.cn

职称：研究员（博士生导师）

地址：伟德官网呈贡校区wedvictor伟德，国家重点实验室1栋1402

教育经历：

1998.09-2001.12，山东大学/德国癌症研究中心，发育生物学，理学博士

1995.09-1998.07，山东大学，细胞生物学，理学硕士

1991.09-1995.07，山东大学，生物化学，理学学士

工作经历：

2023.04-至今，伟德官网，wedvictor伟德，教育部自然资源药物化学重点实验室，研究员

2021.06-2023.04, 伟德官网，教育部自然资源药物化学重点实验室，研究员

2008.01-2021.06，中国科学院昆明植物研究所，研究员

2003.12-2007.12，美国辛辛那提儿童医院医学中心，research fellow

2002.01-2003.11，德国癌症研究中心，博士后

研究领域

围绕肿瘤发生相关信号通路，肿瘤干细胞，肿瘤免疫等，开展肿瘤新靶点，新机制，新药物分子的药理学和化学生物学创新研究。研究成果发表于Nature, Genes& Development, Cell Chemical Biology, Oncogene, Journal of Biological Chemistry, Biochemical Pharmacology等重要期刊。

奖励荣誉和学术任职

云南省“高端科技人才引进计划，2009年度

中国科学院“百人计划”，2010年度

云南省首批“百名海外高层次人才”，2011年度

云南省政府特殊津贴人才，2014年度

执教课程与教学成果

主讲《细胞生物学》，《细胞生物学实验》

主持研究生创新人才培养培养项目：2022年度云南省研究生导师团队建设项目（药理学导师团队）

科研项目

   1) 云南省基础研究计划重点项目，202301AS070022，2023.06-2026.05， 主持

   2) 国家自然科学基金地区项目，32260159，2023.01-2026.12，主持

   3) 伟德官网高层次人才科研启动项目，2021.06-2027.05，主持

   4) 国家自然科学基金面上项目，81773783，2018.01-2021.12，主持

   5) 国家自然科学基金云南省联合基金重点项目，U1402227，2015.01-2018.12，主持

   6) 国家自然科学基金面上项目，81173076，2012.01-2015.12，主持

   7) 云南省首批引进海外高层次人才项目，2012.01-2014.12，主持

   8) 中国科学院“百人计划”择优支持项目，2010.04-2014.04，主持

   9) 云南省高端科技人才引进项目，2009CI120，2009.10-2013.12，主持

   10) 国家重点基础研究发展计划（973）课题，2009CB522305，2009.01-2013.08，主持

代表性论文

1. R Tang, QN Li, HY Zhou, Y Li, T Li, JX Jiang, ZY Chen, LM Kong*, Y Li,* YB Xiao*,HY Sun*. Design, Synthesis, and Biological Evaluation of Novel Activators of Human Caseinolytic Protease P with a Pyrazololactam Scaffold, J. Med. Chem., 2025, 68(10):9984-10007

2. SQ Zhang#, SY Nie#, GC Ma, ML Shen, LM Kong, ZL Zuo*, Y Li*, Identification of novel GSPT1 degraders by virtual screening and bioassay, Eur. J. Med. Chem., 2024, 273:116524

3. YW Li#, HS Wang#, B Sun, GF Su, Y Cang, L Zhao, SH Zhao, Yan Li*, BY Mao*, PC Ma*, Smurf1 and Smurf2 mediated polyubiquitination and degradation of RNF220 suppresses Shh-group medulloblastoma, Cell. Death. Dis., 2023, 14(8):494

4. QH Yang#, T Qin#, T An, HN Wu, G X, J Xiang, KF Lei, SH Zhang, J Xia, GF Su, D Wang, MG X, LM Kong, WX Zhang*, S Wu*, Y Li*, Novel PORCN inhibitor WHN-88 targets Wnt/β-catenin pathway and prevents the growth of Wnt-driven cancers, Eur. J. Pharmacol., 2023, 945:175628

5. F Xiong#, LM Kong#, L Chen, MG Xue, F Cao, SQ Zhang, HM Li, H Yan, Y Li*, ZL Zuo*. Discovery of potential novel CRBN modulators by virtual screening and bioassay. Eur. J. Med. Chem., 2022, 236:114355

6. BC Cai, L Gong, YY Zhu, LM Kong, XM Ju, X Li, XD Yang, HY Zhou,* Y Li*. Identification of Gossypol Acetate as an Autophagy Modulator with Potent Anti-tumor Effect against Cancer Cells. J. Agric. Food Chem. 2022, 70:2589−2599

7. SH  Zhang, XM Ju, QH Yang, YY Zhu, DM Fan, GF Su, LM Kong, Y Li*. USP47 maintains the stemness of colorectal cancer cells and is inhibited by parthenolide. Biochem. Biophys. Res. Commun, 2021, 562:21-28

8.  X Li, LM Kong, QH Yang, AZ Duan, XM Ju, BC Cai, L Chen, T An*, Y Li*. Parthenolide inhibits ubiquitin-specific peptidase 7 (USP7), Wnt signaling, and colorectal cancer cell growth. J. Biol. Chem, 2020, 295: 3576-3589

9. PC Ma #, T An #, L Zhu, LL Zhang, HS Wang, BY Ren, B Sun, X Zhou, Y Li*, BY Mao*. RNF220 is required for cerebellum development and regulates medulloblastoma progression through epigenetic modulation of Shh signaling. Development, 2020, 147, dev188078

10. XZ Su#, YY Zhu#, JW Tang, K Hu, XN Li, HD Sun,Y Li*, PT Puno*. Pestaloamides A and B, two spiro-heterocyclic alkaloid epimers from the plant endophytic fungus Pestalotiopsis sp. HS30. Science China Chemistry, 2020, 63: 1208–1213

11. L Chen, DM Fan, JW Tang, T An, X Li, LM Kong *, PT Puno*, Y Li*. Discovery of isopenicin A, a meroterpenoid as a novel inhibitor of tubulin polymerization. Biochem. Biophys. Res. Commun, 2020, 525:303-307

12. HF Zhu #, B Wang #, LM Kong, T An, GT Li, HY Zhou, L Gong, ZX Zhao, YX Gong, HD Sun, PT Puno*, Y Li*. Parvifoline AA Promotes Susceptibility of Hepatocarcinoma to Natural Killer Cell-Mediated Cytolysis by Targeting Peroxiredoxin. Cell. Chem. Biol, 2019, 26(8):1122-1132

13.  HY Zhou #, CL Yu #, LM Kong #, XL Xu, JM Yan, YC Li, T An, L Gong, YX Gong, HF Zhu, HB Zhang *, XD Yang*, Y Li*. B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells. Oncogene, 2019, 38:3371-3386

14.  JW Tang #, LM Kong #, WY Zu, K Hu, XZ Su, XN Li, BC Yan, WG Wang, HD Sun, Y Li*, PT Puno*. Isopenicins A–C: Two Types of Novel Antitumor Meroterpenoids from the Plant Endophytic Fungus Penicillium sp. sh18. Org. Lett, 2019, 21:771-775

15.   LL Wang #, LM Kong #, H Liu, YQ Zhang, L Zhang, XY Liu, F Yuan, Y Li*, ZL Zuo*. Design and synthesis of novel artemisinin derivatives with potent activities against colorectal cancer in vitro and in vivo. Eur. J. Med. Chem, 2019, 182:111665

16. ZH Gao#, KQ Chen#, Y Zhang, LM Kong, Y Li*, S Ye*. Enantioselective N‑Heterocyclic Carbene-Catalyzed Synthesis of Spirocyclic Oxindole-benzofuroazepinones. J. Org. Chem. 2018, 83:15225−15235

17. T An, YX Gong, X Li, LM Kong, PC Ma, L Gong, HF Zhu, CL Yu, JM Liu, HY Zhou, BY Mao, Y Li*. USP7 inhibitor P5091 inhibits Wnt signaling and coloreal tumor growth. Biochem. Pharmacol, 2017, 131(1):29-39

18.  CL Yu, YX Gong, HY Zhou, M Wang, LM Kong, JM Liu, T An, HF Zhu, Y Li*. Star-PAP, a poly(A) polymerase, functions as a tumor suppressor in an orthpic humanbreast cancer model. Cell Death Dis, 2017, 8 (2): e2582.

19.  LD Shao #, J Su #, BX Ye #, JX Liu #, ZL Zuo, Y Li, YY Wang*, CF Xia*, QS Zhao*. Design, Synthesis, and Biological Activities of Vibsanin B Derivatives: A New Class of HSP90 C-Terminal Inhibitors. J. Med. Chem., 2017, 60 (21): 9053–9066 60(21).

20.  HY Zhou #, CW Shang #, M Wang, T Shen, LM Kong, CL Yu, ZN Ye, Y Luo, L Liu, Y Li*, SL Huang*. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK. Biochem. Pharmacol, 2016, 16:39-50

21. M   Wang, AK Zhou, T An, LM Kong, CL Yu, JM Liu, CF Xia*, HY Zhou*, Y Li*. N-Hydroxyphthalimide exhibits antitumor activity by suppressing mTOR signaling pathway in BT-20 and LoVo cells. J Exp Clin Cancer Res, 2016, 35:41

22. LM  Kong, BY Mao, HJ Zhu *, Y Li*. Novel β-carbolines inhibit Wnt/β-catenin signaling. Cell. Death. Dis., 2015, 6, e1983

23.  XY Li, B Bai, L Liu, PC Ma, LM Kong, JM Yan, J Zhang, ZN Ye, HY Zhou, BY Mao, HJ Zhu*, Y Li*. Novel β-carbolines against colorectal cancer cell growth via inhibition of Wnt/β-catenin signaling. Cell. Death. Discov., 2015, 1:15033

24. Y Li#, SA Rankin#, D Sinner, AP Kenny, PA Krieg, AM Zorn*. Sfrp5 coordinates foregut specification and morphogenesis by antagonizing both canonical and noncanonical Wnt11 signaling. Genes Dev, 2008, 22: 3050-3063